March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback